RESEARCH ARTICLE
Associations between reflux esophagitis and the progression of coronary artery calcification: A cohort study

Yang Won Min¹*, Byeong Geun Song¹*, Hye Seung Kim², Kyunga Kim², Hyuk Lee¹, Byung-Hoon Min¹, Jun Haeng Lee¹, Hee Jung Son¹, Poong-Lyul Rhee¹*, Jae J. Kim¹

1 Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 2 Biostatistics and Clinical Epidemiology Center, Samsung Medical Center, Seoul, South Korea, 3 Center for Health Promotion, Samsung Medical Center, Seoul, South Korea

☯ These authors contributed equally to this work.
* plrhee@skku.edu

Abstract

Background
Reflux esophagitis (RE) and coronary heart disease (CHD) have common risk factors, including obesity and metabolic syndrome. This study aimed to evaluate the associations between RE and the future CHD risk.

Methods
This retrospective cohort study included 8,221 participants who were ≥20 years old, and who underwent esophagogastroduodenoscopy and coronary computed tomography (CT) scans during the same visit and subsequent CT scans between 2003 and 2013. RE was defined as the presence of at least Los Angeles classification grade A mucosal break. CT scan was used to determine the coronary artery calcium (CAC) scores. CAC progression was defined as an increase in the CAC score on a subsequent CT scan.

Results
RE was present in 984 (12.0%) participants. RE at baseline was associated with CAC progression (odds ratio [OR], 1.253; 95% confidence interval [CI], 1.088–1.444; \( P = 0.002 \)), and this association persisted after adjusting the model for age, sex, smoking status, and alcohol consumption (OR, 1.175; 95% CI, 1.001–1.378; \( P = 0.048 \)). This association disappeared when the model was further adjusted for body mass index, diastolic blood pressure, the presence of hypertension, glycated hemoglobin, low-density lipoprotein cholesterol, and triglycerides (OR, 1.088; 95% CI, 0.924–1.281; \( P = 0.311 \)) which were selected using a step-wise selection procedure from several metabolic variables.
Conclusions

Our results suggest that the presence of RE is closely associated with CHD, even though RE is not a direct risk factor for CHD. Metabolic factors may play roles in CAC progression in individuals with RE.

Introduction

Gastroesophageal reflux disease (GERD) is widespread and its global burden is increasing. The GERD prevalence estimates are 18.1%–27.8% in North America, 8.8%–25.9% in Europe, and 2.5%–7.8% in East Asia [1,2]. Evidence suggests that the prevalence of GERD has increased, particularly in North America and East Asia [1]. The most important factor associated with the development of GERD is central obesity [3–6]. Given that obesity is also an important determinant of coronary heart disease (CHD), it is reasonable to assume that GERD may reflect the risk of CHD [7]. Furthermore, GERD and CHD share metabolic syndrome as a common risk factor. However, no data are available that describe the association between GERD and CHD.

The coronary artery calcium (CAC) score is an established marker of subclinical atherosclerosis, and it is an independent predictor of CHD events in the asymptomatic population [8,9]. Furthermore, the progression of the CAC score is closely associated with an increased risk of CHD events, and it even predicts all-cause mortality [10,11]. Hence, CAC scores are widely used to evaluate the risk of CHD. Thus, this study aimed to assess the associations between GERD and the future risk of CHD, which were determined using CAC scoring, in a large cohort of men and women who participated in a health screening program.

Patients and methods

Study design and patient population

This cohort study included 199,375 men and women who were aged ≥20 years and underwent health screening examinations at the Health Promotion Center of the Samsung Medical Center in Seoul, South Korea, from March 1, 2003 to December 31, 2013. Esophagogastroduodenoscopy (EGD) was conducted in all participants since Korea has the high incidence of gastric cancer, and CAC scan was conducted only if the participants wanted to do regardless of cardiovascular risk factor. Given that our objective was to prospectively evaluate the associations between reflux esophagitis (RE) and the changes in the CAC score, only participants who underwent screening EGD and coronary computed tomography (CT) scanning during the same visit were enrolled (n = 27,348). We then excluded participants who did not undergo follow-up coronary CT scans (n = 19,038) and those who had missing information (n = 89). Finally, a total of 8,221 participants who were aged ≥20 years, had undergone EGD and repeated coronary CT scans, and who did not have any data missing were included in the analysis (Fig 1).

This study protocol was conducted in accordance with the Declaration of Helsinki. The Institutional Review Board of the Samsung Medical Center approved the study’s protocol and waived the requirement for informed consent, because we used de-identified data that were routinely collected during the health screening visits.
Data collection

Data describing the participants’ demographics, smoking status, alcohol consumption, and past medical histories were collected using standardized, self-administered questionnaires. Hypertension was defined as a systolic blood pressure (SBP) \( \geq 140 \text{ mmHg} \), a diastolic blood pressure (DBP) \( \geq 90 \text{ mmHg} \), a self-reported history of hypertension, or the current use of anti-hypertensive medications. Diabetes mellitus was defined as fasting serum glucose \( \geq 126 \text{ mg/dL} \), a self-reported history of diabetes, or the self-reported use of insulin or anti-diabetic medications. Dyslipidemia was defined as high-density lipoprotein (HDL) cholesterol \( < 40 \text{ mg/dL} \) in men, HDL cholesterol \( < 50 \text{ mg/dL} \) in women, triglycerides \( \geq 150 \text{ mg/dL} \), or the use of medication for dyslipidemia. Information about the presence of ischemic heart disease and cerebrovascular disease was collected from the participants’ medical records. A participant’s smoking status was categorized as never, past, or current smoker. A participant’s alcohol consumption was categorized as never, past, or current drinker. Trained nurses measured the body mass index (BMI) in kg/m\(^2\), waist circumference (WC) in cm, SBP, and DBP. The glycated hemoglobin (HbA1c), total cholesterol, low-density lipoprotein cholesterol, HDL cholesterol, and triglyceride levels were also measured.

Since there is no gold standard for a diagnosis of GERD, a definition of GERD is usually based on the presence of reflux symptoms. In our study, however, we used the presence of RE as an objective marker of GERD to reduce variability related to symptom reporting. RE was defined as the presence of at least a grade A mucosal break that was detected during EGD, which was based on the Los Angeles classification of esophagitis [12].

Coronary computed tomography

Brilliance 40 (Philips Medical Systems, Cleveland, Ohio), VCT LightSpeed 64 (GE Healthcare, Milwaukee, Wisconsin), or Discovery 750HD (GE Healthcare) multidetector CT scanners were used to acquire images of CAC. The scans were analyzed using Extended Brilliance Workspace (Philips Medical Systems) or Advantage (GE Healthcare) workstations. The CAC scores were calculated as described by Agatston et al. [13].

**Fig 1. Study flow chart.** EGD, esophagogastroduodenoscopy; CT, computed tomography.

https://doi.org/10.1371/journal.pone.0184996.g001
Statistical analysis

The patients’ baseline characteristics were compared according to the RE status using the chi-square test or Student’s t-test. CAC progression was defined as an increase in the CAC score on a subsequent CT scan. To estimate the risk of CAC progression according to the RE status at baseline, odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using logistic regression analysis which deals with CAC changes as a binary variable (increase or not). We further estimated the ORs and 95% CIs using adjusted models, as follows: model 1 was adjusted for age and sex; model 2 was further adjusted for alcohol consumption and the smoking status; and model 3 was further adjusted for BMI, DBP, the presence of hypertension, HbA1c, LDL cholesterol, and triglycerides (log transformed), which were selected using a stepwise selection procedure from several metabolic variables, including BMI, height, weight, SBP, DBP, HbA1c, total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides, and the presence of hypertension, diabetes, dyslipidemia, ischemic heart disease, and cerebrovascular disease. The data were screened for multicollinearity.

All of the P values reported are two-sided, and P values <0.05 were considered statistically significant. SAS version 9.4 (SAS Institute, Cary, NC) was used for the statistical analyses.

Results

The baseline cross sectional analysis (n = 27,348) of those with RE and extent of CAC controlling other factors are shown in Table 1. We included 8,211 participants in the analysis, comprising 7,237 participants who did not have RE and 984 participants who had RE. The study participants’ baseline characteristics are shown in Table 2. The participants’ mean age was 53.8 ±7.7 years, and 12.0% of the participants had RE at baseline (n = 984). Compared to the participants who did not have RE, those who had RE were more likely to be men, current smokers, and current drinkers, and they were more likely to have higher BMIs, DBPs, and triglyceride levels, and lower HDL cholesterol levels, and to be taller and heavier. At baseline, the mean CAC score was higher in the participants who had RE (99.6±276.4) than in those who did not have RE (76.6±202.6) (P = 0.012). The participants who had RE at baseline had a significantly higher CAC progression rate (67.2%) than those who did not have RE at baseline (62.0%) (P = 0.006).

The CAC scores increased in the 4,488 participants who did not have RE at baseline during 28,169.16 person-years of follow-up, and the incidence was 159.3/1,000 person-years. The CAC scores increased in the 661 participants who had RE at baseline during 3,723.78 person-years of follow-up, and the incidence was 177.5/1,000 person-years. A comparison of the participants who had RE with those who did not have RE in the univariate analysis showed that the OR for CAC progression was 1.253 (95% CI, 1.088–1.444; P = 0.002). After adjusting the model for age and sex, the OR for CAC progression was 1.227 (95% CI, 1.058–1.423; P = 0.007). When the model was further adjusted for alcohol consumption and the smoking status and the participants with RE were compared with those who did not have RE, the OR for CAC progression was 1.175 (95% CI 1.001–1.378; P = 0.048). This association disappeared in model 3 that was further adjusted for BMI, DBP, the presence of hypertension, HbA1c, LDL cholesterol, and triglycerides (OR, 1.088; 95% CI, 0.924–1.281; P = 0.311) (Table 3). The results from the multivariate analysis are shown in Table 4.

Discussion

The findings from this large longitudinal study have shown that CAC score progression was more common in individuals who had RE than in those who did not have RE at baseline. This association persisted when the model was adjusted for potential confounders that included
Table 1. Cross sectional univariate and multivariate analyses of the association between reflux esophagitis and coronary artery calcium score.

| Variables               | Univariate analysis | Multivariate analysis |
|-------------------------|---------------------|-----------------------|
|                         | OR (95% CI)         | P value               | OR (95% CI) | P value |
| Reflux esophagitis      | 1.316 (1.221–1.419) | <0.001                | 1.199 (1.100–1.307) | <0.001 |
| BMI (kg/m²)             | 1.090 (1.080–1.100) | <0.001                | 1.090 (1.070–1.111) | <0.001 |
| Height (cm)             | 1.000 (0.997–1.003) | 0.930                 |             |         |
| Weight (kg)             | 1.016 (1.014–1.019) | <0.001                | 0.986 (0.981–0.991) | <0.001 |
| Smoking status          |                     |                       |             |         |
| Never                   | 1                   |                       |             |         |
| Past smoker             | 1.695 (1.592–1.804) | <0.001                | 1.738 (1.618–1.866) | <0.001 |
| Current smoker          | 1.265 (1.184–1.351) | <0.001                | 1.252 (1.159–1.352) | <0.001 |
| Alcohol consumption     |                     |                       |             |         |
| Never                   | 1                   |                       |             |         |
| Past drinker            | 1.667 (1.282–2.167) | <0.001                | 1.434 (1.082–1.901) | 0.012  |
| Current drinker         | 1.060 (0.997–1.128) | <0.062                | 0.994 (0.922–1.072) | 0.871  |
| SBP (mmHg)              | 1.015 (1.014–1.017) | <0.001                | 1.015 (1.012–1.018) | <0.001 |
| DBP (mmHg)              | 1.014 (1.012–1.016) | <0.001                | 0.992 (0.988–0.995) | <0.001 |
| HbA1c (%)               | 1.667 (1.605–1.732) | <0.001                | 1.571 (1.503–1.642) | <0.001 |
| Total cholesterol (mg/dL) | 1.000 (1.000–1.001) | 0.391                 |             |         |
| LDL-C (mg/dL)           | 1.001 (1.000–1.002) | 0.024                 | 1.001 (1.000–1.002) | 0.020  |
| HDL-C (mg/dL)           | 0.988 (0.987–0.990) | <0.001                | 0.993 (0.990–0.995) | <0.001 |
| Triglycerides (mg/dL)²  | 1.001 (1.001–1.002) | <0.001                | 1.000 (1.000–1.000) | 0.819  |
| Hypertension            | 1.784 (1.633–1.950) | <0.001                | 1.415 (1.263–1.585) | <0.001 |
| Diabetes                | 2.163 (1.871–2.500) | <0.001                | 0.910 (0.754–1.098) | 0.323  |
| Dyslipidemia            | 1.296 (1.173–1.432) | <0.001                | 0.935 (0.824–1.061) | 0.298  |
| Ischemic heart disease  | 3.070 (2.121–4.444) | <0.001                | 1.952 (1.259–3.026) | 0.003  |
| Cerebrovascular disease | 1.985 (1.116–3.530) | 0.020                 | 0.828 (0.391–1.752) | 0.622  |

OR, odds ratio; CI, confidence interval; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol.

OR, odds ratio; CI, confidence interval; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol. Log transformed.

https://doi.org/10.1371/journal.pone.0184996.t001

age, sex, alcohol consumption, and the smoking status. However, the association disappeared when the model was adjusted further for BMI, DBP, the presence of hypertension, HbA1c, LDL cholesterol, and triglycerides. These findings indicate that RE could predict future CAC progression. While RE is not a direct risk factor for CAC progression, metabolic factors may play roles in CAC progression in individuals with RE.

The results from this study are consistent with those from previous studies [14,15]. Chen et al. [15] conducted a population-based cohort study that included 12,960 patients who had GERD and 51,840 who did not have GERD, and they showed that the risk of CHD was greater for the GERD cohort (adjusted hazard ratio, 1.49; 95% CI, 1.34–1.66; P < 0.001). Additionally, Shah et al. [14] reported that patients with GERD who had been exposed to proton pump inhibitors had a 1.16-fold increased association with myocardial infarction (95% CI, 1.09–1.24), and that this association existed regardless of the use of clopidogrel. However, these studies had important limitations, because several potential confounding factors, including BMI, WC, blood pressure, and the lipid profiles were not considered; hence, the association between GERD and CHD may have been overestimated. On the other hand, the current study incorporated detailed information about the metabolic parameters. Using high quality clinical, imaging, and laboratory procedures improved the robustness of this study's data.
Obesity and, especially, abdominal obesity, is a strong independent risk factor for GERD [4,16]. Gastroesophageal reflux (GER) occurs when the intragastric pressure is greater than the intraesophageal pressure. An increased pressure gradient between the stomach and the esophagus is present in individuals who have high BMIs [17]. In addition to the mechanical effect of the increased pressure gradient on GER promotion, central adiposity has a BMI-independent effect on the risk of RE [18]. Recently, esophageal inflammation involving a cytokine-mediated pathway, rather than reflux, has been proposed as a mechanism that underlies the pathogenesis of RE [19]. In addition, previous studies’ findings have shown that metabolic syndrome and GERD are independently associated [16,20–23]. Chung et al. analyzed 7,078 adult men and women who had participated in health screening examinations, and they showed that metabolic syndrome was associated with RE (OR, 1.42; 95% CI, 1.26–1.60) after adjusting for multiple confounders [16]. Collectively, these findings suggest that we should not view RE as just a

| Table 2. Baseline characteristics of the study participants according to the reflux esophagitis status. |
|---------------------------------------------------------------|
|                                                                 |
| **Overall (n = 8,221)**                                       | **Reflux esophagitis status** | **p value** |
| **Negative (n = 7,237)**                                     | **Positive (n = 984)**        |             |
| Age (years)                                                   | 53.8±7.7                     | 53.8±7.7    | 0.891          |
| Male sex                                                      | 7,481 (91)                   | 6,516 (90)  | <0.001         |
| BMI (kg/m²)                                                   | 24.7±2.6                     | 24.6±2.6    | <0.001         |
| Height (cm)                                                   | 169.4±6.7                    | 169.3±6.8   | <0.001         |
| Weight (kg)                                                   | 71.1±9.5                     | 70.8±9.5    | <0.001         |
| Smoking status                                                |                               |             | <0.001         |
| Never                                                         | 2,221 (30.6)                 | 2,062 (32.2) | 159 (18.6) |
| Past smoker                                                   | 3,295 (45.4)                 | 2,918 (45.6) | 377 (44.1) |
| Current smoker                                                | 1,740 (24.0)                 | 1,421 (22.2) | 319 (37.3) |
| Alcohol consumption                                          |                               |             | <0.001         |
| Never                                                         | 1,332 (17.0)                 | 1,231 (17.9) | 101 (10.7) |
| Past drinker                                                  | 26 (0.3)                     | 24 (0.4)    | 2 (0.2)      |
| Current drinker                                               | 6,466 (82.6)                 | 5,626 (81.8) | 840 (91.1) |
| CAC score >0                                                  | 4,932 (60.0)                 | 4,302 (59.4) | 630 (64.0) |
| CAC difference (final—baseline) >0                           | 5,149 (62.6)                 | 4,488 (62.0) | 661 (67.2) |
| CAC score (Agatston units)                                    | 79.3±212.9                   | 76.6±202.6  | 99.6±276.4   |
| SBP (mmHg)                                                    | 119.4±15.6                   | 119.3±15.6  | 120.2±15.4   |
| DBP (mmHg)                                                    | 75.7±10.5                    | 75.5±10.5   | 77.0±10.5   |
| HbA1c (%)                                                     | 5.6±0.8                      | 5.63±0.7    | 5.68±0.9    |
| Total cholesterol (mg/dL)                                     | 198.6±34.2                   | 198.7±34.1  | 197.9±35.0  |
| LDL-C (mg/dL)                                                | 128.4±31.0                   | 128.6±30.9  | 126.8±31.6  |
| HDL-C (mg/dL)                                                | 51.8±12.7                    | 52.1±12.7   | 49.8±12.0   |
| Triglycerides (mg/dL)                                         | 147.2±88.1                   | 145.0±86.2  | 163.0±99.6  |
| Hypertension                                                 | 631 (7.7)                    | 553 (7.6)   | 78 (7.9)    |
| Diabetes                                                     | 239 (2.9)                    | 210 (2.9)   | 29 (3.0)    |
| Dyslipidemia                                                 | 538 (6.5)                    | 485 (6.7)   | 53 (5.4)    |
| Ischemic heart disease                                       | 28 (0.3)                     | 26 (0.4)    | 2 (0.2)     |
| Cerebrovascular disease                                       | 8 (0.1)                      | 5 (0.1)     | 3 (0.3)     |

BMI, body mass index; CAC, coronary artery calcium; SBP, systolic blood pressure; DBP, diastolic blood pressure; HbA1c, glycated hemoglobin; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol. The data presented are the means±standard deviations or numbers (percentages).

https://doi.org/10.1371/journal.pone.0184996.t002
gastrointestinal problem and that it should be considered as at least one manifestation of metabolic syndrome.

Several prospective studies’ findings have shown that metabolic abnormalities and obesity are associated with an increased risk of CHD [24–29]. The findings from an observational cohort study of 19,173 participants showed that obesity and metabolic syndrome were associated with increased risks of all-cause and CHD-related mortality [26]. Similarly, the findings from two large prospective cohort studies showed that BMI and WC strongly predicted the future risk of CHD [29]. Furthermore, the findings from a recent meta-analysis of 14 prospective cohort studies demonstrated the combined effects of obesity and metabolic abnormalities on the risks of CHD and mortality [30]. In the present study, CAC progression was used as an indicator of future CHD events. Previous studies’ findings have shown that CAC progression was closely associated with metabolic syndrome [31,32].

There are some limitations to our study. First, this study was conducted on asymptomatic Korean men and women who attended regular health screening examinations, and our findings may not be generalizable to other populations. Second, only individuals who underwent EGD and repeated coronary CT scans were enrolled in this study, which may have caused a selection bias. However, given that CAC scan was optional screening test that subjects decided whether to receive, the effect of selection bias would be small. However, our study has several strengths that include its longitudinal design, large sample size, and the availability of detailed information about many metabolic parameters. In addition, the current study is the first to establish a relationship between RE and CAC progression in a longitudinal investigation.

In conclusion, RE was associated with CAC progression. However, the association disappeared after the model was adjusted for the metabolic parameters, which suggests that metabolic factors may play roles in CAC progression in individuals with RE. Our results suggest that the presence of RE could be closely associated with CHD, even though RE is not a direct risk factor associated with CHD. Thus, individuals who are diagnosed with RE should be aware of coronary atherosclerosis and try to modify the risk factors associated with CHD as well as receive acid suppressive or antireflux therapy for esophagitis.

| Reflex esophagitis status | Negative (n = 7,237) | Positive (n = 984) | P value |
|--------------------------|---------------------|--------------------|---------|
| Follow-up duration (years) | 3.9±2.2             | 3.8±2.1             | 0.178   |
| Person-years             | 28,169.2            | 3,723.8            |         |
| Incident cases of CAC progression | 4,488              | 661                |         |
| Incidence rate per 1,000 person-years | 159.3              | 177.5              |         |

CAC, coronary artery calcium. Values in parenthesis are the 95% confidence intervals. Model 1: Adjusted for age and sex. Model 2: Further adjusted for baseline smoking status (never, past, or current), and alcohol consumption (never, past, or current). Model 3: Further adjusted for body mass index, diastolic blood pressure, hypertension, glycated hemoglobin, low-density lipoprotein-cholesterol, and triglycerides (log$_e$-transformed).
### Table 4. Univariate and multivariate analyses of the association between reflux esophagitis and coronary artery calcium score progression.

| Variables                | Univariate analysis | Multivariate analysis |
|--------------------------|---------------------|-----------------------|
|                         | OR (95% CI)         | P value               | OR (95% CI)         | P value |
| Reflux esophagitis       | 1.253 (1.088–1.444) | 0.002                 | 1.088 (0.924–1.281) | 0.311  |
| Age (years)              | 1.091 (1.084–1.099) | <0.001                | 1.101 (1.092–1.111) | <0.001 |
| Sex (male)               | 1.165 (0.999–1.359) | 0.051                 | 1.442 (1.155–1.802) | 0.001  |
| BMI (kg/m²)              | 1.086 (1.067–1.106) | <0.001                | 1.071 (1.048–1.094) | <0.001 |
| Height (cm)              | 0.983 (0.976–0.989) | <0.001                |                    |        |
| Weight (kg)              | 1.010 (1.005–1.015) | <0.001                |                    |        |
| Smoking status           |                     |                       |                     |        |
| Never                    | 1                    |                       | 1                    | <0.001 |
| Past smoker              | 1.266 (1.134–1.414) | <0.001                | 1.256 (1.100–1.434) | 0.001  |
| Current smoker           | 1.115 (0.980–1.267) | 0.097                 | 1.345 (1.154–1.568) | <0.001 |
| Alcohol consumption      |                     |                       |                     |        |
| Never                    | 1                    |                       | 1                    | 0.756  |
| Past drinker             | 1.117 (0.482–2.590) | 0.796                 | 0.915 (0.362–2.310) | 0.850  |
| Current drinker          | 0.801 (0.707–0.908) | 0.010                 | 0.940 (0.800–1.106) | 0.458  |
| SBP (mmHg)               | 1.013 (1.010–1.016) | <0.001                |                    |        |
| DBP (mmHg)               | 1.014 (1.010–1.018) | <0.001                | 1.013 (1.008–1.019) | <0.001 |
| HbA1c (%)                | 1.658 (1.533–1.792) | <0.001                | 1.397 (1.284–1.519) | <0.001 |
| Total cholesterol (mg/dL)| 1.002 (1.000–1.003) | 0.010                 |                    |        |
| LDL-C (mg/dL)            | 1.002 (1.000–1.003) | 0.021                 | 1.004 (1.002–1.005) | <0.001 |
| HDL-C (mg/dL)            | 0.992 (0.998–0.996) | <0.001                |                    |        |
| Triglycerides (mg/dL)¹   | 1.001 (1.001–1.002) | <0.001                | 1.001 (1.000–1.002) | 0.003  |
| Hypertension             | 1.650 (1.376–1.977) | <0.001                | 1.566 (1.270–1.932) | <0.001 |
| Diabetes                 | 1.690 (1.263–2.261) | <0.001                |                    |        |
| Dyslipidemia             | 1.267 (1.051–1.527) | 0.013                 |                    |        |
| Ischemic heart disease   | 2.752 (1.045–7.247) | 0.040                 |                    |        |
| Cerebrovascular disease  | 0.994 (0.237–4.164) | 0.994                 |                    |        |

OR, odds ratio; CI, confidence interval; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol.

¹log_e transformed.

https://doi.org/10.1371/journal.pone.0184996.t004

---

**Supporting information**

**S1 File.** This file contains detailed information for the statistical analyses of this study. (XLS)

**Author Contributions**

**Conceptualization:** Yang Won Min, Byeong Geun Song, Hyuk Lee, Byung-Hoon Min, Jun Haeng Lee, Hee Jung Son, Poong-Lyul Rhee, Jae J. Kim.

**Data curation:** Yang Won Min, Byeong Geun Song.

**Formal analysis:** Yang Won Min, Byeong Geun Song, Hye Seung Kim, Kyunga Kim, Poong-Lyul Rhee.

**Investigation:** Yang Won Min, Byeong Geun Song, Poong-Lyul Rhee.
Methodology: Yang Won Min, Byeong Geun Song, Hye Seung Kim, Kyunga Kim, Hyuk Lee, Byung-Hoon Min, Jun Haeng Lee, Hee Jung Son, Poong-Lyul Rhee, Jae J. Kim.

Project administration: Yang Won Min, Byeong Geun Song.

Supervision: Poong-Lyul Rhee.

Writing – original draft: Yang Won Min, Byeong Geun Song.

Writing – review & editing: Yang Won Min, Byeong Geun Song.

References

1. El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014; 63: 871–880. https://doi.org/10.1136/gutjnl-2012-304269 PMID: 23853213

2. Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2005; 54: 710–717. https://doi.org/10.1136/gut.2004.051821 PMID: 15831922

3. El-Serag HB, Ergun GA, Pandolfini J, Fitzgerald S, Tran T, Kramer JR. Obesity increases oesophageal acid exposure. Gut. 2007; 56: 749–755. https://doi.org/10.1136/gut.2006.100263 PMID: 17127706

4. El-Serag HB, Graham DY, Satia JA, Rabeneck L. Obesity is an independent risk factor for GERD symptoms and erosive esophagitis. Am J Gastroenterol. 2005; 100: 1243–1250. https://doi.org/10.1111/j.1572-0241.2005.01703.x PMID: 15929752

5. Friedenberg FK, Xanthopoulos M, Foster GD, Richter JE. The association between gastrooesophageal reflux disease and obesity. Am J Gastroenterol. 2008; 103: 2111–2122. https://doi.org/10.1111/j.1572-0241.2008.01946.x PMID: 18796104

6. Fisher BL, Pennathur A, Mutnick JL, Little AG. Obesity correlates with gastroesophageal reflux. Dig Dis Sci. 1999; 44: 2290–2294. https://doi.org/10.1023/A:102661706755 PMID: 10573376

7. Lanas F, Seron P, Munoz S, Margozzini P, Puig T. Central obesity measurements better identified risk factors for coronary heart disease risk in the Chilean National Health Survey (2009–2010). J Clin Epidemiol. 2016

8. Osaka K, Nakanishi R, Budoff M. Coronary Artery Calcification. Glob Heart. 2016; 11: 287–293. https://doi.org/10.1016/j.ghart.2016.08.001 PMID: 27741976

9. Polonsky TS, McClelland RL, Jorgensen NW, Bild DE, Burke GL, Guerci AD, et al. Coronary artery calcium score and risk classification for coronary heart disease prediction. Jama. 2010; 303: 1610–1616. https://doi.org/10.1001/jama.2010.461 PMID: 20424251

10. Budoff MJ, Hohanson JE, Nasir K, Shaw LJ, Kinney GL, Chow D, et al. Progression of coronary artery calcium predicts all-cause mortality. JACC Cardiovascular Imaging. 2010; 3: 1229–1236. https://doi.org/10.1016/j.jcmg.2010.08.018 PMID: 21163451

11. Budoff MJ, Young R, Lopez VA, Kronmal RA, Nasir K, Blumenthal RS, et al. Progression of coronary calcium and incident coronary heart disease events: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2013; 61: 1231–1239. https://doi.org/10.1016/j.jacc.2012.12.035 PMID: 23500326

12. Wong RK, Yeoh KG, Gwee KA, Tay HW, Ho KY. Validation of structured scoring using the LA classification for esophagitis and endoscopically suspected Barrett’s esophagus in a tertiary Asian endoscopy center. J Gastroenterol Hepatol. 2009; 24: 103–106. https://doi.org/10.1111/j.1440-1746.2008.05680.x PMID: 19054260

13. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Vielmonte M Jr., Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990; 15: 827–832. PMID: 2407762

14. Shah NH, LePendu P, Bauer-Mehren A, Ghebrehiwet AT, Iyer SV, Marcus J, et al. Proton Pump Inhibitor Use and the Risk of Myocardial Infarction in the General Population. PLoS One. 2015; 10: e0124653. https://doi.org/10.1371/journal.pone.0124653 PMID: 26061035

15. Chen CH, Lin CL, Kao CH. Association between gastroesophageal reflux disease and coronary heart disease: A nationwide population-based analysis. Medicine (Baltimore). 2016; 95: e4089. https://doi.org/10.1097/md.0000000000004089 PMID: 27399102

16. Chung SJ, Kim D, Park MJ, Kim YS, Kim JS, Jung HC, et al. Metabolic syndrome and visceral obesity as risk factors for reflux esophagitis: a cross-sectional case-control study of 7078 Koreans undergoing health check-ups. Gut. 2008; 57: 1360–1365. https://doi.org/10.1136/gut.2007.147090 PMID: 18441006
17. Derakhshan MH, Robertson EV, Fletcher J, Jones GR, Lee YY, Wirz AA, et al. Mechanism of association between BMI and dysfunction of the gastro-oesophageal barrier in patients with normal endoscopy. Gut. 2012; 61: 337–343. https://doi.org/10.1136/gutjnl-2011-300633 PMID: 21873737

18. Singh S, Sharma AN, Murad MH, Buttar NS, El-Serag HB, Katzka DA, et al. Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013; 11: 1399–1412.e1397. https://doi.org/10.1016/j.cgh.2013.05.009 PMID: 23707461

19. Dunbar KB, Agoston AT, Odze RD, Pham TH, Cipher DJ, et al. Association of Acute Gastroesophageal Reflux Disease With Esophageal Histologic Changes. JAMA. 2016; 315: 2104–2112. https://doi.org/10.1001/jama.2016.5657 PMID: 27187303

20. Niigaki M, Adachi K, Hirakawa K, Furuta K, Kinoshita Y. Association between metabolic syndrome and prevalence of gastroesophageal reflux disease in a health screening facility in Japan. J Gastroenterol. 2013; 48: 463–472. https://doi.org/10.1007/s00535-012-0671-3 PMID: 22976934

21. Chua CS, Lin YM, Yu FC, Hsu YH, Chen JH, Yang KC, et al. Metabolic risk factors associated with erosive esophagitis. J Gastroenterol Hepatol. 2009; 24: 1375–1379. https://doi.org/10.1111/j.1440-1746.2009.05858.x PMID: 19467140

22. Loke SS, Yang KD, Chen KD, Chen JF. Erosive esophagitis associated with metabolic syndrome, impaired liver function, and dyslipidemia. World J Gastroenterol. 2013; 19: 5883–5888. https://doi.org/10.3748/wjg.v19.i35.5883 PMID: 24124334

23. Watanabe S, Hojo M, Nagahara A. Metabolic syndrome and gastrointestinal diseases. J Gastroenterol. 2007; 42: 267–274. https://doi.org/10.1007/s00535-007-2033-0 PMID: 17464445

24. Kip KE, Marroquin OC, Kelley DE, Johnson BD, Kelsey SF, Shaw LJ, et al. Clinical importance of obesity versus the metabolic syndrome in cardiovascular risk in women: a report from the Women's Ischemia Syndrome Evaluation (WISE) study. Circulation. 2004; 109: 706–713. https://doi.org/10.1161/01.CIR.0000115514.44135.A8 PMID: 14970104

25. St-Pierre AC, Cantin B, Mauriege P, Bergeron J, Dagenais GR, Despres JP, et al. Insulin resistance syndrome, body mass index and the risk of ischemic heart disease. Cmaj. 2005; 172: 1301–1305. https://doi.org/10.1503/cmaj.1040834 PMID: 15883404

26. Katzmarzyk PT, Church TS, Janssen I, Ross R, Blair SN. Metabolic syndrome, obesity, and mortality: impact of cardiorespiratory fitness. Diabetes Care. 2005; 28: 391–397. https://doi.org/10.2337/diacare.28.2.391 PMID: 15677798

27. Katzmarzyk PT, Janssen I, Ross R, Church TS, Blair SN. The importance of waist circumference in the definition of metabolic syndrome: prospective analyses of mortality in men. Diabetes Care. 2006; 29: 404–409. https://doi.org/10.2337/diacare.29.02.06.dc05-1636 PMID: 16443895

28. Flint AJ, Hu FB, Glynn RJ, Caspard H, Manson JE, Willett WC, et al. Excess weight and the risk of incident coronary heart disease among men and women. Obesity (Silver Spring). 2010; 18: 377–383. https://doi.org/10.1038/oby.2009.223 PMID: 19629058

29. Flint AJ, Rexrode KM, Hu FB, Glynn RJ, Caspard H, Manson JE, et al. Body mass index, waist circumference, and risk of coronary heart disease: A prospective study among men and women. Obes Res Clin Pract. 2010; 4: e163–246. https://doi.org/10.1016/j.orecop.2010.01.001 PMID: 24345660

30. Fan J, Song Y, Chen Y, Hui R, Zhang W. Combined effect of obesity and cardio-metabolic abnormality on the risk of cardiovascular disease: a meta-analysis of prospective cohort studies. Int J Cardiol. 2013; 168: 4761–4768. https://doi.org/10.1016/j.ijcard.2013.07.230 PMID: 23972953

31. Ryu J, Yong HS, Huh S, Kang EY, Woo OH. Relation of coronary atherosclerosis and metabolic syndrome in asymptomatic subjects: evaluation with coronary CT angiography. Int J Cardiovasc Imaging. 2013; 29 Suppl 2: 101–107. https://doi.org/10.1007/s10554-013-0319-2 PMID: 24186238

32. Kim LK, Yoon JW, Lee DH, Kim KM, Choi SH, Park KS, et al. Impact of metabolic syndrome on the progression of coronary calcium and of coronary artery disease assessed by repeated cardiac computed tomography scans. Cardiovasc Diabetol. 2016; 15: 92. https://doi.org/10.1186/s12933-016-0404-7 PMID: 27352620